Alle weiteren Präsentationen unter https://boerse-social.com/austrianworldwideroadshow
Marinomed - Solving the unsolvable with radical innovation (08.06.2021)
Marinomed - Disclaimer (08.06.2021)
Marinomed - Highlights (08.06.2021)
Marinomed - Q1 Highlights (08.06.2021)
Marinomed - Market (08.06.2021)
Marinomed - Snapshot on business drivers (08.06.2021)
Marinomed - R&D progress/pipeline (08.06.2021)
Marinomed - Marinomed pipeline (08.06.2021)
Marinomed - Carragelose neutralizes SARS-CoV-2 in vitro (08.06.2021)
Marinomed - SARS-CoV-2 prophylaxis trial in health care professionals with iota-carrageenan (08.06.2021)
Marinomed - Ongoing SARS-CoV-2 clinical trials with iota-carrageenan (08.06.2021)
Marinomed - SARS-CoV-2 and its variants will stay with us (08.06.2021)
Marinomed - Carragelose® – Clinically validated for the prevention of COVID-19 (08.06.2021)
Marinomed - Carragelose® Products (08.06.2021)
Marinomed - Marinomed Pipeline (08.06.2021)
Marinomed - Marinosolv® development status (08.06.2021)
Marinomed - Budesolv and Flutisolv target the dynamic Allergic Rhinitis (AR) market (08.06.2021)
Marinomed - Phase II clinical trial for Tacrosolv in allergic conjunctivitis (08.06.2021)
Marinomed - Tacrosolv – potential game changer in the treatment of inflammatory eye diseases (08.06.2021)
Marinomed - Financials (08.06.2021)
Marinomed - Significant year-over-year growth also for Q1 (08.06.2021)
Marinomed - Statement of profit or loss (08.06.2021)
Marinomed - Statement of financial position (IFRS) (08.06.2021)
Marinomed - Statement of financial position (IFRS) (08.06.2021)
Marinomed - Outlook (08.06.2021)
Marinomed - Strong development, however, with uncertainty in timing (08.06.2021)
Marinomed - Stay Healthy! (08.06.2021)
Marinomed - www.marinomed.com (08.06.2021)
Marinomed - Investor Relations Contact (08.06.2021)
Emil Schulthess & Hans Ulrich Meier
Ed van der Elsken
Max Zerrahn